Arvee Laboratories (India) Ltd (NSE: ARVEE) is an Ahmedabad, Gujarat-based company in the Custom Synthesis and Specialty CDMO industry. With a market capitalisation of ₹251 Cr, it ranks #2,463 by market cap among the 6,197 Indian listed companies on FinBizNet, and #10 of 13 in Custom Synthesis and Specialty CDMO. At ₹222.00 (as of 16 Nov 2026), the share price is 23.7% below its 52-week high of ₹290.78 and 71.9% above its 52-week low of ₹129.11. The share price is up 39.6% over one year and up 31.6% over three months.
| Current Price | ₹222.00 |
|---|---|
| Market Cap | ₹251 Cr |
| NSE Symbol | ARVEE |
| Sector | Materials > Chemicals > Speciality Chemicals |
| Sub-Industry | Specialty Chemicals > Custom Synthesis and Specialty CDMO |
| P/E Ratio | 100 |
| Return on Equity | 7.78% |
| Return on Assets | 3.07% |
| 52-Week Range | ₹129.11 – ₹290.78 |
| 1-Year Price Change | +39.6% |
| 3-Month Price Change | +31.6% |
| Beta (1Y) | 0.06 |
| Headquarters | Ahmedabad, Gujarat |
| Website | arveelabs.com |
| Revenue | ₹25 Cr |
|---|---|
| Net Profit | ₹3 Cr |
| Net Margin | 10.3% |
| EPS (Basic) | ₹2.32 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Arvee Laboratories (India) Ltd reported revenue of ₹25 Cr in Q2 FY27, up 622.6% from ₹3 Cr in Q2 FY26 and up 44.7% from ₹17 Cr in Q1 FY27. It posted a net profit of ₹3 Cr for the quarter, against a net profit of ₹0 Cr in Q2 FY26 (up 25500.0%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹3 Cr (Q2 FY26) to ₹25 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹25 Cr | ₹3 Cr | 10.3% |
| Q1 FY27 | ₹17 Cr | ₹2 Cr | 9.8% |
| Q4 FY26 | ₹11 Cr | ₹1 Cr | 4.8% |
| Q3 FY26 | ₹10 Cr | ₹2 Cr | 18.7% |
| Q2 FY26 | ₹3 Cr | ₹0 Cr | 0.3% |
| Q1 FY26 | ₹7 Cr | ₹0 Cr | 2.3% |
| Q4 FY25 | ₹6 Cr | ₹0 Cr | 1.1% |
Standalone figures (₹ crore, XBRL filings).
Promoters held 73.50% of Arvee Laboratories (India) Ltd's shares as of Sept 2026, unchanged from Sept 2025. Delivery averaged 63.3% of traded volume across 14 NSE sessions (22 Oct 2026 – 11 Nov 2026).
Arvee Laboratories (India) Ltd. manufactures and sells various specialized chemicals in India. The company offers polymer modifiers, including dimethyl 5-sodiosulfoisophthalate, 5-sulfoisophthalic acid mono sodium salt, 5-sulfoisophthalic acid mono lithium salt, and 5-sodiosulfo-bis-(ß-hydroxyethyl)-isophthalate; and contrast media intermediates, such as 5-nitroisophthalic acid, dimethyl 5-nitroisophthalate, monomethyl 5-nitroisophthalate, 5-hydroxyisophthalic acid, 5-aminoisophthalic acid, and dimethyl 5-aminoisophthalate, as well as 3,5-dinitrobenzoic acid and 3,5-diamino benzoic acid. It also provides drug intermediates comprising 2-acetyl thiophene, thiophene-2-carboxaldehyde, 4–amino pyridine, and 2–chloro–5–nitrobenzoic acid. In addition, the company exports its products. Arvee Laboratories (India) Ltd. was incorporated in 2012 and is based in Ahmedabad, India.
1. Chemicals-This segment manufactures and sells various chemicals and pharmaceutical intermediates.
1. Chemicals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Anupam Rasayan India Ltd | ₹13,570 Cr | 79.6 | 5.76% | ₹806 Cr | +20.1% |
| Neogen Chemicals Limited (Neogen) | ₹8,322 Cr | 259.2 | 3.58% | ₹296 Cr | +93.4% |
| Prasol Chemicals Limited | ₹4,681 Cr | 58.1 | — | ₹413 Cr | — |
| Laxmi Organic Industries Ltd | ₹4,574 Cr | 57.2 | 4.08% | ₹1,083 Cr | -18.9% |
| Tatva Chintan Pharma Chem Ltd | ₹3,871 Cr | 92.5 | 5.53% | ₹217 Cr | +12.2% |
| Paushak Ltd. | ₹1,487 Cr | 38.1 | 8.22% | ₹89 Cr | — |
| Sunshield Chemicals Ltd. | ₹833 Cr | 25.2 | 17.02% | — | +12.6% |
| Chemcon Speciality Chemicals Limited | ₹733 Cr | 31.8 | 4.80% | ₹65 Cr | -12.8% |
| Arvee Laboratories (India) Ltd | ₹251 Cr | 100 | 7.78% | ₹25 Cr | +39.6% |
Listed by market capitalisation. Ratios are shown for context only.
Arvee Laboratories (India) Ltd is trading at ₹222.00, with a market capitalisation of ₹251 Cr.
Arvee Laboratories (India) Ltd operates in the Materials > Chemicals > Speciality Chemicals space (Specialty Chemicals > Custom Synthesis and Specialty CDMO).
Arvee Laboratories (India) Ltd has a P/E of 100 and a return on equity of 7.78%.
Arvee Laboratories (India) Ltd is listed on the NSE under the symbol ARVEE.
Arvee Laboratories (India) Ltd's share price is up 39.6% over one year and up 31.6% over three months. Its 52-week range is ₹129.11 to ₹290.78.
In Q2 FY27, Arvee Laboratories (India) Ltd reported revenue of ₹25 Cr and net profit of ₹3 Cr, with basic EPS of ₹2.32 (standalone, parsed from the company's exchange filing).
Arvee Laboratories (India) Ltd reported revenue of ₹25 Cr in Q2 FY27, up 622.6% from ₹3 Cr in Q2 FY26 and up 44.7% from ₹17 Cr in Q1 FY27.
Promoters held 73.50% of Arvee Laboratories (India) Ltd's shares as of Sept 2026, unchanged from Sept 2025.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.